LifeWatcher Targets Emerging Markets
Tokyo-based Mobile Healthcare closes deal with Jean-Michel Halfon, past President of Emerging Markets at Pfizer, details: http://bit.ly/qzNRLN
Hearty Congrats to James Nakagawa and Co. as they have been on this mission for many years. It’s really super to see their Made in Japan service will continue to reach new and needed markets.. [Eds]
Mobile Healthcare Inc., and Jean-Michel Halfon, immediate past President of Pfizer Emerging Markets Business Unit (EMBU), Announces a Collaboration to Contribute to Chronic Disease Prevention & Management in Emerging Markets
Tokyo, July 21, 2011 – Mobile Healthcare Inc (“MHC”), a pioneering mobile health company and home to the global award winning lifewatcher cell phone and cloud-based health management platform, is pleased to announce today that it has initiated collaboration with Jean-Michel Halfon to contribute to the expansion of the company as an advisor and investor. Official PR Here.
“I am thrilled to collaborate with Mobile Healthcare and with his CEO James Nakagawa”, said Jean-Michel Halfon. “I am humbled by the impressive accomplishments of MHC following the introduction of its flagship lifewatcher cloud platform and impressed by its potential contribution to patients and healthcare systems worldwide”. According to a recent report of the Lancet, rates of diabetes have doubled globally since 1980 reaching 347 million patients showing the imperious need to leverage technology to offer affordable solutions to patients for prevention and management of diabetes.
“I am excited at the opportunity to work with Jean-Michel and benefit from his broad expertise and industry leadership in healthcare and emerging markets,” said James Nakagawa Founder, CEO and Chief Care Architect of MHC.
In Q1 2011, Jean-Michel Halfon completed his 32-year career at Pfizer in his most recent position as President of the Emerging Markets Business Unit (EMBU). Jean-Michel launched the EMBU in January of 2009 and established commercial hubs across five international regions in more than 70 countries. In addition to delivering strong performances,
Jean-Michel focused on leading innovative efforts to increase access to medicines for underserved patients, and on forming pioneering partnerships with new kinds of external stakeholders. Jean-Michel graduated from École Centrale Paris and holds an MBA from HEC-ISA in France.